Expression of cyclin-dependent kinase inhibitor p21 in human liver

被引:60
|
作者
Crary, GS
Albrecht, JH
机构
[1] Hennepin Cty Med Ctr, Dept Med 865B, Minneapolis, MN 55415 USA
[2] Hennepin Cty Med Ctr, Dept Pathol, Minneapolis, MN 55415 USA
关键词
D O I
10.1002/hep.510280320
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The p21 protein is a universal inhibitor of cyclin-dependent kinases and of cell-cycle progression and is involved in numerous growth-inhibitory pathways in cell culture systems. Recent studies suggest that p21 regulates hepatocyte cell cycle progression in models of liver regeneration. The present study was designed to investigate the possible involvement of p21 in the control of hepatocyte proliferation in human liver diseases. To examine that, the expression of p21 in clinical liver biopsy specimens was determined by immunohistochemistry. This was correlated with hepatocyte Ki-67 immunostaining (a marker of hepatocyte proliferation in vivo) as well as histologic features. Little p21 or Ki-67 expression was detected in normal human liver or in specimens of nonalcoholic steatohepatitis, In patients with alcoholic hepatitis, increased expression of p21, but not of Ki-67, was observed. In specimens with chronic hepatitis C, hepatocyte p21 expression was significantly correlated with Ki-67 immunostaining, as well as with the degree of inflammation and fibrosis. These results indicate that hepatocyte p21 expression is upregulated in response to hepatic injury and correlates with histologic markers of proliferation and disease activity. This study provides evidence that p21 plays a role in the regulation of hepatocyte proliferation in human liver diseases.
引用
收藏
页码:738 / 743
页数:6
相关论文
共 50 条
  • [1] Purification and crystallization of cyclin-dependent kinase inhibitor p21
    Mayrose, DR
    Nichols, MA
    Yue, XO
    Ke, HM
    [J]. PROTEIN SCIENCE, 1996, 5 (09) : 1928 - 1930
  • [2] The role of the cyclin-dependent kinase inhibitor p21 in apoptosis
    Gartel, AL
    Tyner, AL
    [J]. MOLECULAR CANCER THERAPEUTICS, 2002, 1 (08) : 639 - 649
  • [3] Cyclin-dependent kinase inhibitor p21 in endometrial carcinoma
    Backe, J
    Caffier, H
    Dietl, J
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 177 (01) : 243 - 243
  • [4] IFNα induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells
    Amy C Hobeika
    Prem S Subramaniam
    Howard M Johnson
    [J]. Oncogene, 1997, 14 : 1165 - 1170
  • [5] Regulation of the cyclin-dependent kinase inhibitor p21 by an inhibitor of the mevalonate pathway
    Haque, RM
    Lee, SJ
    Nguyen, PM
    Choi, YH
    Pernia, F
    Jang, JS
    Wang, XF
    Kim, SJ
    Trepel, JB
    [J]. MOLECULAR BIOLOGY OF THE CELL, 1997, 8 : 801 - 801
  • [6] The cyclin-dependent kinase inhibitor p21 as a target for differentiation therapy
    Manfredi, JJ
    Tang, HY
    Waxman, S
    [J]. MOLECULAR AND CELLULAR DIFFERENTIATION, 1996, 4 (01): : 33 - 45
  • [7] IFN alpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells
    Hobeika, AC
    Subramaniam, PS
    Johnson, HM
    [J]. ONCOGENE, 1997, 14 (10) : 1165 - 1170
  • [8] THE P21 CYCLIN-DEPENDENT KINASE INHIBITOR SUPPRESSES TUMORIGENICITY IN-VIVO
    YANG, ZY
    PERKINS, ND
    OHNO, T
    NABEL, EG
    NABEL, GJ
    [J]. NATURE MEDICINE, 1995, 1 (10) : 1052 - 1056
  • [9] Polymorphisms of p21 cyclin-dependent kinase inhibitor and malignant skin tumors
    Konishi, R
    Sakatani, S
    Kiyokane, K
    Suzuki, K
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2000, 24 (03) : 177 - 183
  • [10] P53-INDEPENDENT EXPRESSION OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P21 IN PANCREATIC-CARCINOMA
    DIGIUSEPPE, JA
    REDSTON, MS
    YEO, CJ
    KERN, SE
    HRUBAN, RH
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1995, 147 (04): : 884 - 888